Key findings

There does not appear to be any significant efficacy or safety differences in transitioning patients with schizophrenia from paliperidone palmitate (PP) 3 months (PP3M) to paliperidone palmitate 6 months (PP6M) long-acting injectable (LAI) for preventing relapse.

No new safety signals emerged for the European subgroups; the most common ...